XOMA ROYALTY CORP - XOMA 8 5/8 PERP (XOMAP) Stock News
NASDAQ:XOMAP - Nasdaq - US98419J3059 - Currency: USD
XOMAP Latest News, Press Relases and Analysis
XOMA Royalty Completes Sale of Kinnate Pipeline Assets
XOMA Royalty sold the remaining Kinnate pipeline assets for a total of up to $270 million in upfront and milestone payments, plus royalties on commercial...
Mentions: XOMA
XOMA Royalty Completes Sale of Kinnate Pipeline Assets
Mentions: XOMA
XOMA Royalty to Present at Jones Healthcare and Technology Innovation Conference
EMERYVILLE, Calif., April 02, 2025 (GLOBE NEWSWIRE) -- XOMA Royalty Corporation (“XOMA”; NASDAQ: XOMA), the biotech royalty aggregator, announced today...
Mentions: XOMA
XOMA Royalty to Present at Jones Healthcare and Technology Innovation Conference
Mentions: XOMA
XOMA Royalty Declares Quarterly Preferred Stock Dividends
Mentions: XOMA
XOMA Royalty Declares Quarterly Preferred Stock Dividends
EMERYVILLE, Calif., March 20, 2025 (GLOBE NEWSWIRE) -- XOMA Royalty Corporation (Nasdaq: XOMA) today announced its Board of Directors has authorized the...
Mentions: XOMA
XOMA Royalty Declares Quarterly Preferred Stock Dividends
Mentions: XOMA
XOMA Royalty Reports Fourth Quarter and Full Year 2024 Financial Results and Highlights Business Achievements
Doubled the royalty and milestone portfolio to over 120 royalty assets with significant milestone potential through five transactions in 2024 Completed...
Mentions: XOMA
XOMA Royalty Reports Fourth Quarter and Full Year 2024 Financial Results and Highlights Business Achievements
Mentions: XOMA
XOMA Declares Quarterly Preferred Stock Dividends
July 2024 Dividends...
Mentions: XOMA
XOMA Royalty to Present at Investor Conferences in March
EMERYVILLE, Calif., Feb. 24, 2025 (GLOBE NEWSWIRE) -- XOMA Royalty Corporation (NASDAQ: XOMA), the biotech royalty aggregator, announced today members of...
Mentions: XOMA
XOMA Royalty to Present at Investor Conferences in March
Mentions: XOMA
XOMA Royalty to Present at Oppenheimer 35th Annual Healthcare Life Sciences Conference
EMERYVILLE, Calif., Feb. 04, 2025 (GLOBE NEWSWIRE) -- XOMA Royalty Corporation (NASDAQ: XOMA), the biotech royalty aggregator, announced today members of...
Mentions: XOMA
XOMA Royalty to Present at Oppenheimer 35th Annual Healthcare Life Sciences Conference
Mentions: XOMA
XOMA Royalty Declares Quarterly Preferred Stock Dividends
XOMA Royalty January 2025 Dividend Record and Payment Dates...
Mentions: XOMA
XOMA Royalty Declares Quarterly Preferred Stock Dividends
Mentions: XOMA
XOMA Royalty Acquires Pulmokine for $20 Million Adding the Royalty and Milestone Interest in Seralutinib, a Phase 3 Asset, to Its Portfolio
Seralutinib becomes XOMA Royalty’s seventh Phase 3 royalty asset, further building the late-stage pipeline beyond its six current commercial royalty assets...
Mentions: XOMA
XOMA Royalty Acquires Pulmokine for $20 Million Adding the Royalty and Milestone Interest in Seralutinib, a Phase 3 Asset, to Its Portfolio
Mentions: XOMA
XOMA Royalty Reports Third Quarter 2024 Financial Results and Highlights Recent Activities
Zevra’s MIPLYFFA™ (arimoclomol) received FDA approval and became the sixth commercial asset in XOMA Royalty’s portfolio XOMA Royalty acquired a 50 percent...
Mentions: XOMA
XOMA Royalty Reports Third Quarter 2024 Financial Results and Highlights Recent Activities
Mentions: XOMA
XOMA Royalty Significantly Expands its Royalty and Milestone Portfolio with the Addition of Over 60 Early-Stage Programs from Twist Bioscience
XOMA Royalty acquires 50% economic interest in portfolio of 60-plus early-stage assets with $15M payment to Twist Bioscience...
Mentions: XOMA
XOMA Royalty Significantly Expands its Royalty and Milestone Portfolio with the Addition of Over 60 Early-Stage Programs from Twist Bioscience
Mentions: XOMA
Zevra’s MIPLYFFA™ (arimoclomol) Receives Approval from U.S. Food and Drug Administration for Use in Patients with Niemann-Pick Disease Type C (NPC)
MIPLYFFA(TM) becomes 6th commercial asset in XOMA Royalty's portfolio...
Mentions: XOMA
Zevra’s MIPLYFFA™ (arimoclomol) Receives Approval from U.S. Food and Drug Administration for Use in Patients with Niemann-Pick Disease Type C (NPC)
Mentions: XOMA
XOMA Royalty Declares Quarterly Preferred Stock Dividends
Mentions: XOMA
XOMA Royalty to Present at Upcoming Investor Conferences in September
EMERYVILLE, Calif., Sept. 04, 2024 (GLOBE NEWSWIRE) -- XOMA Royalty Corporation (NASDAQ: XOMA), the biotech royalty aggregator, announced today members...
Mentions: XOMA
XOMA Royalty to Present at Upcoming Investor Conferences in September
Mentions: XOMA
XOMA Royalty Reports Second Quarter 2024 Financial Results and Highlights Recent Activities
Cash receipts totaled $22.6 million in 2Q24, inclusive of royalty income and milestones from Day One Pharmaceuticals and Rezolute Expanded the...
Mentions: XOMA
XOMA Royalty Reports Second Quarter 2024 Financial Results and Highlights Recent Activities
Mentions: XOMA
XOMA Receives $8.1 Million Milestone Related to Day One Biopharmaceuticals’ Sale of its Priority Review Voucher
EMERYVILLE, Calif., June 12, 2024 (GLOBE NEWSWIRE) -- XOMA Corporation (NASDAQ: XOMA), the biotech royalty aggregator, announced today it has received an...
Mentions: XOMA
XOMA Receives $8.1 Million Milestone Related to Day One Biopharmaceuticals’ Sale of its Priority Review Voucher
Mentions: XOMA
XOMA to Present at H.C. Wainwright 2nd Annual Bioconnect Investor Conference at NASDAQ
EMERYVILLE, Calif., May 14, 2024 (GLOBE NEWSWIRE) -- XOMA Corporation (NASDAQ: XOMA), the biotech royalty aggregator, announced today that members of its...
Mentions: XOMA
XOMA to Present at H.C. Wainwright 2nd Annual Bioconnect Investor Conference at NASDAQ
Mentions: XOMA
XOMA Reports First Quarter 2024 Financial Results and Highlights Recent Activities
Mentions: XOMA
XOMA Adds Economic Interests in Three First-in-Category Assets to its Royalty and Milestone Portfolio Including XACIATO™ (clindamycin phosphate) Vaginal Gel 2%
Organon, a global women’s healthcare company, initiated XACIATO™ commercial activities in the fourth quarter of 2023 XOMA further expands its late-stage...
Mentions: XOMA